CLINICAL PHARMACOGENOMICS SERVICE AT KFSH&RC ENHANCES DRUG EFFECTIVENESS, PATIENT SAFETY

KUALA LUMPUR, Oct 25 (Bernama) -- The King Faisal Specialist Hospital and Research Centre (KFSH&RC) has launched the inaugural phase of its clinical pharmacogenomics service within its Heart Centre.

This pioneering service leverages the patient's DNA to tailor drug dosages and selections, heralding a new era in healthcare that prioritises personalised treatment for each individual, which is poised to enhance treatment outcomes and reduce potential harm.

In a statement, KFSH&RC's experts have said this analysis empowered physicians to prescribe medications customised to each patient, factoring in their unique health conditions and genetic traits.

This innovative service is a collaborative endeavour between the Centre for Genomic Medicine, Healthcare Information Technology Affairs, and the Pharmaceutical Care Department at KFSH&RC.

In its initial phase, this service encompasses six of the most frequently prescribed medications, as determined by hospital data, whose efficacy is known to be influenced by genetic variations.

KFSH&RC has made it clear that it remains committed to expanding the scope of this service progressively, encompassing all hospital departments.

This expansion underscores the hospital's unwavering dedication to providing personalised healthcare to every patient, ensuring the utmost level of safety, and minimising harm, while adhering to the latest globally endorsed scientific practices.

At the Global Health Exhibition held in Riyadh from Oct 29 to 31, where KFSH&RC plays a vital role as a strategic health partner, the hospital is set to unveil the innovative service that promises to advance healthcare outcomes in the region.

-- BERNAMA